降阶梯、经验性抗生素治疗HBV相关慢加急性肝衰竭合并自发性腹膜炎的效果比较

肝脏 ›› 2021, Vol. 26 ›› Issue (8): 892-894.

降阶梯、经验性抗生素治疗HBV相关慢加急性肝衰竭合并自发性腹膜炎的效果比较

韩仙芝, 张淑凤, 高广甫, 朱海洋, 高红伟, 孙会卿

450052 河南郑州大学第五附属医院消化三科

收稿日期:2020-09-19 出版日期:2021-08-31 发布日期:2021-09-29
通讯作者: 张淑凤,Email:sufei_zhang@126.com
基金资助:
河南省科技攻关计划项目(152102310056)

A comparison between the effects of antibiotic de-escalation therapy and empirical treatment on HBV-related acute-on-chronic liver failure patients complicated with spontaneous bacterial peritonitis

HAN Xian-zhi, ZHANG Shu-feng, GAO Guang-fu, ZHU Hai-yang, GAO Hong-wei, SUN Hui-qing

Department No.3 Digestive Department,The Fifth Affiliated Hospital of Zhengzhou University, Henan 450052, China

Received:2020-09-19 Online:2021-08-31 Published:2021-09-29
Contact: ZHANG Shu-feng,Email:sufei_zhang@126.com

摘要/Abstract

摘要： 目的研究降阶梯与经验性抗生素治疗HBV相关慢加急性重型乙型肝炎(HBV-ACLF)合并自发性腹膜炎(SBP)的疗效。方法 2014年4月至2020年4月104例HBV-ACLF合并SBP患者,采用随机数字表法将104例患者分为观察组和对照组,每组52例。观察组行降阶梯治疗,对照组行经验性治疗。比较两组治疗效果,记录腹水细菌培养结果,分析影响治疗效果的相关因素。结果两组2周时总体疗效比较,差异有统计学意义(P<0.05)。观察组肝性脑病13例,顽固性腹水11例,对照组分别为23例和21例,两组肝性脑病和顽固性腹水发生率比较,差异有统计学意义(P<0.05)。观察组显效患者国际标准化比值(INR)、天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)及终末期肝病模型评分(MELD)显著低于非显效者,差异有统计学意义(P<0.05)。Logistic多因素回归分析显示肝性脑病(95%CI=1.154～9.328,P=0.026,OR=3.281)、肝肾综合征(95%CI=1.522～4.087,P=0.000,OR=2.494)、INR(95%CI=1.375～2.603,P=0.000,OR=1.892)及MELD(95%CI=1.054～3.630,P=0.033,OR=1.956)是HBV-ACLF合并SBP患者疗效的独立影响因素。结论降阶梯方案治疗HBV-ACLF合并SBP患者疗效显著,优于常规经验性抗生素方案,但其临床疗效还受患者INR、MELD及肝性脑病等并发症因素影响。

关键词: 降阶梯, 经验性抗生素, HBV相关慢加急性肝衰竭, 自发性腹膜炎

Abstract: Objective To study on the effect of antibiotic de-escalation therapy and empirical treatment on HBV-related acute-on-chronic liver failure (HBV-ACLF) patients complicated with spontaneous bacterial peritonitis (SBP).Methods A total of 104 patients with HBV-ACLF and SBP from April 2014 to April 2020 were enrolled in this study. They were divided into an observation group and a control group by random number table method, with 52 cases in each group. The observation group was treated with antibiotic de-escalation and further divided into effective and non-effective subgroups, while the control group was treated with empirical antibiotic therapy. The ascites bacterial culture results were recorded and the therapeutic effects of these groups were compared. Factors associated with the treatment effect were analyzed.Results There was significant difference between the observation and control groups in overall efficacy after 2 weeks’ treatment (P<0.05). The incidence of hepatic encephalopathy and refractory ascites in the observation group were significantly lower than those of the control group ((13 vs 23 cases, and 11 vs 21 cases, respectively) (P<0.05). In patients of the observation group, the international normalized ratio (INR), levels of aspartate aminotransferase (AST) and alanine transferase (ALT), the model for end stage liver disease (MELD) score of effectively treated patients were significantly lower than those of non-effective patients (P<0.05). By multivariate logistic regression analysis it was showed that the hepatic encephalopathy (95%CI=1.154～9.328, P=0.026, OR=3.281), hepatorenal syndrome (95%CI=1.522～4.087, P=0.000, OR=2.494), international normalized ratio (INR) (95%CI=1.375～2.603, P=0.000, OR=1.892), model for end-stage liver disease (MELD)(95%CI=1.054-3.630, P=0.033, OR=1.956) were independent factors influencing the treatment effect on patients with HBV-ACLF and SBP.Conclusion Antibiotic de-escalation regimen for the treatment of HBV-ACLF combined with SBP is more effective than conventional empirical antibiotic therapy. This efficacy is further associated with factors such as INR, MELD and hepatic encephalopathy.

Key words: Antibiotic de-escalation, Empirical antibiotic therapy, HBV-related acute-on-chronic liver failure, Spontaneous bacterial peritonitis

韩仙芝, 张淑凤, 高广甫, 朱海洋, 高红伟, 孙会卿. 降阶梯、经验性抗生素治疗HBV相关慢加急性肝衰竭合并自发性腹膜炎的效果比较[J]. 肝脏, 2021, 26(8): 892-894.

HAN Xian-zhi, ZHANG Shu-feng, GAO Guang-fu, ZHU Hai-yang, GAO Hong-wei, SUN Hui-qing. A comparison between the effects of antibiotic de-escalation therapy and empirical treatment on HBV-related acute-on-chronic liver failure patients complicated with spontaneous bacterial peritonitis[J]. Chinese Hepatolgy, 2021, 26(8): 892-894.

参考文献

[1] 刘政芳,黄伟,李芹.慢加急性肝衰竭合并自发性细菌性腹膜炎的危险因素分析.临床肝胆病杂志,2017,33:719-722.
[2] Maini MK, Burton AR. Restoring, releasing or replacing adaptive immunity in chronic hepatitis B.Nat Rev Gastro Hepat, 2019,16:662-675.
[3] 隋玲玲,路丽红,孟昭斌.抗菌药物降阶梯疗法联合支气管肺泡灌洗术治疗急性脑梗死患者肺部感染的临床疗效.中华医院感染学杂志,2015,25:4679-4681.
[4] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊治指南(2018年版).实用肝脏病杂志,2019,22:164-171.
[5] Ofliver EAF. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.J Hepatol,2010,53:397-417.
[6] 中国医药教育协会感染疾病专业委员会, 中华结核和呼吸杂志编辑委员会, 中国药学会药物临床评价研究专业委员会. 抗菌药物超说明书用法专家共识.中华结核和呼吸杂志,2015,38:410-444.
[7] 中华医学会肝病学分会.肝硬化腹水及相关并发症的诊疗指南.实用肝脏病杂志,2018,21:21-31.
[8] 赵正斌,范文海,陈青锋, 等.肝硬化并自发性细菌性腹膜炎患者腹水培养的病原菌分布及耐药性分析.临床荟萃,2016,31:1222-1224.
[9] Protic D, Pejovic A, Djukanovic N, et al. Analysis of the third- and fourth-generation cephalosporin use for the treatment of infections caused by Gram-negative bacteria in hospital settings.Int J Clin Pract, 2016, 70:1033-1040.
[10] Fiore M. Letter: the emergence of multi‐drug resistant spontaneous bacterial peritonitis: a new challenge for the hepatologist.Aliment Pharmacol Ther,2016,43:944–945.
[11] 焦栓林,赵晓蕊,欧阳洪, 等.复方甘草酸苷联合激素降阶梯治疗38例重型酒精性肝炎的临床疗效观察.肝脏,2017,22:818-820.
[12] 李雷清,韩国丽,吴丹梅, 等.重症监护病房抗菌药物降阶梯治疗策略实施情况调查.中华临床感染病杂志,2015,8:31-35.
[13] 李文刚,徐小元.失代偿性肝硬化患者合并肾损伤与肝肾综合征的管理.中华肝脏病杂志, 2020,28:381-385.
[14] Blasi A, Calvo A, Prado, Verónica, et al. Coagulation failure in patients with Acute-on-Chronic Liver Failure (ACLF) and decompensated cirrhosis: beyond INR. Hepatology, 2018,68:2325-2337.
[15] 张静,周新民.5种评分系统对慢加急性肝衰竭患者短期病死率的预测价值.临床肝胆病杂志,2019,35:1990-1994.